Skip to main content
SpringerLink
Log in

Personalized treatment with atypical antipsychotic medications

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

The considerable pharmacologic differences among atypical antipsychotic agents and the specific clinical circumstances of individual patients with psychiatric illness require the availability of a full range of agents in this class. Restrictions in the availability of atypical agents may prove to be counterproductive, both clinically and economically. Elderly individuals and those from minority groups may be particularly disadvantaged by restrictions placed on these agents. Additional clinical studies in large populations with different forms of schizophrenia and varied clinical histories are required to determine the appropriateness of specific atypical agents in patient subgroups. Advances in knowledge of the molecular genetics of schizophrenia and the receptor properties of individual drugs will help the clinician determine which drug and dosage are best for each individual patient. This will eventually replace the “hit or miss” process that characterizes current practice. Because of variations in response to atypical agents, the clinical vulnerability of patients with psychiatric illness, the difficulties they have in adapting to changes and adhering to medication regimens, and our poor understanding of the molecular basis of schizophrenia and its treatment, prescription insurance plans should provide access to a broad range of atypical agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wakade CG, Mahadik SP, Waller JL, Chiu FC. Atypical neuroleptics stimulate neurogenesis and the adult rat brain.J Neurosci Res. 2002;69:72–79.

    Article  PubMed  CAS  Google Scholar 

  2. Lieberman JA, Tollefson GD, Charles C, et al. Antipsychotic drug effects on brain morphology in first-episode psychosis.Arch Gen Psychiatry. 2005;62:361–370.

    Article  PubMed  CAS  Google Scholar 

  3. American Association for Geriatric Psychiatry (AAGP).Position Paper on Formulary Choices and Restrictions. Bethesda, Md: AAGP; 1997.

    Google Scholar 

  4. MedPAC. Dual eligible beneficiaries. Available at: http://www.medpac.gov/publications/ congressional_reports/Jun04DatabookSec2.pdf. June 30, 2007.

  5. Donohue J. Mental health in the Medicare Part D benefit: a new regulatory model?Health Affairs. 2006;25:707–719.

    Article  PubMed  Google Scholar 

  6. Morden NE, Garrison LP Jr. Implications of Part D for mentally ill dual eligibles: a challenge for Medicare.Health Affairs. 2006;25:491–500.

    Article  PubMed  Google Scholar 

  7. Smedley BD, Stith AY, Nelson AR, eds.Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: The National Academies Press; 2003.

    Google Scholar 

  8. Opolka JL, Rascati KL, Brown CM, Gibson PJ. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.Psychiatr Serv. 2004;55:151–156.

    Article  PubMed  Google Scholar 

  9. Henderson D. Ethnopharmacology update. Presented at: The American Psychiatric Association 2005 Annual Meeting; May 21–26, 2005; Atlanta, Ga. Symposium No. 15A.

  10. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better.J Clin Psychiatry. 2003;64:1308–1315.

    Article  PubMed  Google Scholar 

  11. Surles RC. Atypical antipsychotics: considerations for Medicaid coverage.Am J Manag Care. 2005;11(suppl):S248-S253.

    PubMed  Google Scholar 

  12. Kane JM. Schizophrenia.N Engl J Med. 1996;334:34–41.

    Article  PubMed  CAS  Google Scholar 

  13. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.Psychiatr Serv. 2004;55:886–891.

    Article  PubMed  Google Scholar 

  14. Muller N. Mechanisms of relapse prevention in schizophrenia.Pharmacopsychiatry. 2004; 37(suppl 2):S141-S147.

    Article  PubMed  Google Scholar 

  15. Tandon R, Nasrallah HA. The diagnosis and treatment of schizophrenia in primary care: Medscape Psychiatry and Mental Health CME Program. Available at: http://www.medscape.com/ viewprogram/5902. Accessed September 13, 2006.

  16. Parikh V, Evans DR, Khan MM, Mahadik SP. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome.Schizophrenia Res. 2003;60:117–123.

    Article  Google Scholar 

  17. Osterberg L, Blaschke T. Adherence to medication.N Engl J Med. 2005;353:487–497.

    Article  PubMed  CAS  Google Scholar 

  18. Chue PS, Heeg BMS, Buskens E, van Hout BA. Modeling the impact of compliance on the costs and effects of long-acting risperidone in Canada.PharmacoEconomics. 2005;23(suppl 1):62–74.

    Article  PubMed  Google Scholar 

  19. Edwards NC, Rupnow MF, Pashos CL, Botteman MF, Diamond RJ. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.PharmacoEconomics. 2005;23(suppl 1):299–314.

    Article  PubMed  CAS  Google Scholar 

  20. Soumerai S. Unintended outcomes of Medicaid drug cost-containment policies on the chronically mentally ill.J Clin Psychiatry. 2003;64(suppl 17):19–22.

    PubMed  Google Scholar 

  21. Tamblyn R. Evaluation report on the impact of the prescription drug insurance plan: Summary Report submitted to the Ministere de la Sante et des Services Sociaux du Quebec, March 1999.

  22. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost sharing among poor and elderly persons.JAMA. 2001;285:421–429.

    Article  PubMed  CAS  Google Scholar 

  23. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid: AARP research report #2004–04, March 2004, Washington, DC. Available at: http://assets.aarp.org/ rgcenter/health/2004_04_access.pdf. Accessed November 6, 2006.

  24. Committee for Program Review and Investigations, Legislative Research Commission. Program evaluation of the Kentucky Medicaid Drug File and Prior Authorization System: report on the impact of prior authorization for Zyprexa. Research Report No. 281, November 2003. Frankfort, Kentucky: Kentucky Medicaid Program; May 1999.

  25. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum A, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.Value Health. 2006;9:77–89.

    Article  PubMed  Google Scholar 

  26. Soumerai S. Implications of research on drug cost containment for the Medicare drug benefit: balancing access, affordability and innovation. Presented at: The Health Industry Forum, Balancing Access, Affordability, and Innovation: Pharmaceutical Benefit Management Under Medicare Part D; July 13, 2006; Waltham, Mass.

  27. McCombs J.Anti-psychotics and interchangeability. Presented at: The P& T Society 6th Annual Conference: Impact of Public Policy vs. Market Reality; October 26–27, 2006; Washington, DC.

  28. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.N Engl J Med. 2005;353:1209–1223.

    Article  PubMed  CAS  Google Scholar 

  29. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.Am J Psychiatry. 2003;160:1209–1222.

    Article  PubMed  Google Scholar 

  30. Rosack J. Government antipsychotic study finds no clear winner in “horse race.”Psychiatric News. October 21, 2005;40:1.

    Google Scholar 

  31. National Alliance on Mental Illness. CATIE raises more questions than it answers. Available at: http://www.nami.org/Template.cfm?Section=CATIE&Template=/ContentManagement/ ContentDisplay.cfm&ContentID=27164. Accessed November 3, 2006.

  32. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.Am J Psychiatry. 2007;164:415–427.

    Article  PubMed  Google Scholar 

  33. NIMH perspective on antipsychotic reimbursement: using results from CATIE, October 31, 2005. Available at: http://www.nami.org/Template.cfm?Section=CATIE&Template=/ ContentManagement/ContentDisplay.cfm&ContentID=27931. Accessed October 19, 2006.

  34. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications.Am J Psychiatry. 2006;163:2090–2095.

    Article  PubMed  Google Scholar 

  35. Tamminga C. Practical treatment information for schizophrenia.Am J Psychiatry. 2006;163:563–565.

    Article  PubMed  Google Scholar 

  36. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor activity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology. 2003;28:519–526.

    Article  PubMed  CAS  Google Scholar 

  37. American Psychiatric Association (APA).Practice Guideline for the Treatment of Patients With Schizophrenia. 2nd ed. Arlington, Va: APA; 2004.

    Google Scholar 

  38. Keefe RS. Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone. Presented at: 18th Congress of the European College of Neuropsychopharmacology; October 22–25, 2005; The Netherlands. Late-Breaking Session, Abstract 5.

  39. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.Schizophrenia Bull. 1999;25:201–222.

    CAS  Google Scholar 

  40. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.Schizophrenia Bull. 1999;25:233–355.

    CAS  Google Scholar 

  41. Meltzer HY, Lee MA, Ranjan R. Recent advances in the pharmacotherapy of schizophrenia.Acta Psychiatr Scand. 1994;90(suppl):95–101.

    Article  Google Scholar 

  42. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response.Lancet. 2000;55:1615–1616.

    Article  Google Scholar 

  43. Mizutani T. Frequencies of major CYPs in Asians and Caucasians.Drug Metab Rev. 2003;35:99–106.

    Article  PubMed  CAS  Google Scholar 

  44. De Leon J, Susce MT, Pan R-M, Fairchild M, Koch WH, Wedlund PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation.Clin Psychiatry. 2005;66:15–27.

    Article  Google Scholar 

  45. Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.J Clin Psychopharmacol. 2000;20:246–251.

    Article  PubMed  CAS  Google Scholar 

  46. Ginsberg DL, ed. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry.CNS Spectr. 2006;11 (suppl 3):1–16.

  47. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharma-cogenetic testing for CYP450 2D6 and CYP450 2C19.Psychosomatics. 2006;47:75–85.

    Article  PubMed  Google Scholar 

  48. Sharif ZA. Pharmacokinetics, metabolism, and drug-drug interactions of atypical antipsychotics in specialized populations.J Clin Psychiatry. 2003;5(suppl 6):22–25.

    Google Scholar 

  49. Scharfetter J. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia—an update.Pharmacogenomics. 2004;5:691–698.

    Article  PubMed  CAS  Google Scholar 

  50. Lencz T, Robinson DG, Xu K, et al. DRT2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.Am J Psychiatry. 2006;163:529–531.

    Article  PubMed  Google Scholar 

  51. Lane HY, Lee CC, Liu YC, Chang WH. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.Pharmacogenomics. 2005;6:139–149.

    Article  PubMed  CAS  Google Scholar 

  52. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response.Am J Psychiatry. 2004;161:780–796.

    Article  PubMed  Google Scholar 

  53. Ruaño G, Goethe JW, Caley C, et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.Mol Psychiatry. 2007;12:474–482.

    PubMed  Google Scholar 

  54. Wilffert B, Zaal R, Brouwers JR. Pharmacogenetics as a tool in the therapy of schizophrenia.Pharm World Sci. 2005;27:20–30.

    Article  PubMed  CAS  Google Scholar 

  55. Templeman LA, Reynolds GP, Arranz B, San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.Pharmacogenet Genomics. 2005;15:195–200.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Outcomes Research USA Global Epidemiology and Outcomes Research, Bristol-Myers Squibb Company, Plainsboro, New Jersey

    Edward Kim MD, MBA (Associate Director)

  2. Levy Consulting, Bethesda, Maryland

    Richard Levy PhD (Principal)

  3. Medical Affairs, Otsuka America Pharmaceutical Inc., Rockville, Maryland

    Andrei Pikalov MD, PhD (Senior Director)

Authors
  1. Edward Kim MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Levy PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrei Pikalov MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Levy PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, E., Levy, R. & Pikalov, A. Personalized treatment with atypical antipsychotic medications. Adv Therapy 24, 721–740 (2007). https://doi.org/10.1007/BF02849966

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02849966

Keywords

Search

Navigation